What is the role of rituximab in the treatment of hemophilia A?

Updated: Jan 14, 2019
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Rituximab, a chimeric human-mouse monoclonal antibody against CD20 that rapidly and specifically depletes B cells, has been used with success in ITI. [41, 42] A 4-week course of weekly rituximab, with or without prednisone and/or cyclophosphamide, has shown durable and complete responses in several small trials in patients with autoimmune hemophilia and inhibitor titers of 5 to more than 200 BU. [43] Rituximab appears to be more effective in treating inhibitors in acquired hemophilia than in hereditary hemophilia. [44, 45]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!